Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduction of blood loss in pediatric osteotomies around the hip with tranexamic acid
2024-516324-34-01Phase 4Authorised
- Sponsor
- Erasmus MC
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in Slipped Capital Femoral Epiphysis (SCFE), Legg-Calvé-Perthes disease (LCPD), muscle diseases (NMD) and 1 more comparing Tranexamic acid with Placebo (saline) (2 arms). Primary endpoint: Estimated intraoperative blood loss (ml/kg). Planned start Nov 2024; status: authorised.
02
Drugs
tranexamic acid
03
Conditions
Slipped Capital Femoral Epiphysis (SCFE)Legg-Calvé-Perthes disease (LCPD)muscle diseases (NMD)hip dysplasia (DDH)
Beyond the preview
Go deeper on 2024-516324-34-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516324-34-01.